Bushen Tiansui decoction is composed of six traditional Chinese medicines：Herba Epimedii,Radix Polygoni multiflori,Plastrum testudinis,Fossilia Ossis Mastodi,Radix Polygalae,and Rhizoma Acorus tatarinowii.Because Bus...Bushen Tiansui decoction is composed of six traditional Chinese medicines：Herba Epimedii,Radix Polygoni multiflori,Plastrum testudinis,Fossilia Ossis Mastodi,Radix Polygalae,and Rhizoma Acorus tatarinowii.Because Bushen Tiansui decoction is effective against amyloid beta（Aβ） toxicity,we hypothesized that it would reduce hippocampal synaptic damage and improve cognitive function in Alzheimer＇s disease.To test this hypothesis,we used a previously established animal model of Alzheimer＇s disease,that is,microinjection of aggregated Aβ25–35 into the bilateral brain ventricles of Sprague-Dawley rats.We found that long-term（28 days） oral administration of Bushen Tiansui decoction（0.563,1.688,and 3.375 g/m L;4 m L/day） prevented synaptic loss in the hippocampus and increased the expression levels of synaptic proteins,including postsynaptic density protein 95,the N-methyl-D-aspartate receptor 2 B subunit,and Shank1.These results suggested that Bushen Tiansui decoction can protect synapses by maintaining the expression of these synaptic proteins.Bushen Tiansui decoction also ameliorated measures reflecting spatial learning and memory deficits that were observed in the Morris water maze（i.e.,increased the number of platform crossings and the amount of time spent in the target quadrant and decreased escape latency） following intraventricular injections of aggregated Aβ25–35 compared with those measures in untreated Aβ_（25–35）-injected rats.Overall,these results provided evidence that further studies on the prevention and treatment of dementia with this traditional Chinese medicine are warranted.展开更多
[目的]观察复元填髓方治疗小脑共济失调综合征患者的疗效。[方法]纳入2024年2月至10月温州市中西医结合医院门诊就诊的小脑共济失调综合征患者29例,予以复元填髓方汤剂治疗12周,对比治疗前后患者国际合作共济失调量表(International Coo...[目的]观察复元填髓方治疗小脑共济失调综合征患者的疗效。[方法]纳入2024年2月至10月温州市中西医结合医院门诊就诊的小脑共济失调综合征患者29例,予以复元填髓方汤剂治疗12周,对比治疗前后患者国际合作共济失调量表(International Cooperative Ataxia Scale,ICARS)、共济失调等级量表(Scale for the Assessment and Rating of Ataxia,SARA)、日常生活活动能力(Activities of Daily Living,ADL)评分及中医证候量表的变化。[结果]共29例患者入组,其中27例完成12周疗程(脱落2例),治疗后患者ICARS评分缓解率为55.6%,维持率为25.9%;治疗前ICARS评分为(35.85±12.90)分,治疗后为(34.33±13.10)分,差异有统计学意义(P<0.05);SARA评分及中医症候量表评分均显著降低(P<0.05)。治疗期间,患者不良反应率为11.1%,其中腹泻3例。[结论]复元填髓方能够改善小脑共济失调综合征患者的共济失调症状以及肾虚髓亏证候。展开更多
基金supported by the National Natural Science Foundation of China,No.81373705the Natural Science Foundation of Hunan Province in China,No.13JJ3030
文摘Bushen Tiansui decoction is composed of six traditional Chinese medicines：Herba Epimedii,Radix Polygoni multiflori,Plastrum testudinis,Fossilia Ossis Mastodi,Radix Polygalae,and Rhizoma Acorus tatarinowii.Because Bushen Tiansui decoction is effective against amyloid beta（Aβ） toxicity,we hypothesized that it would reduce hippocampal synaptic damage and improve cognitive function in Alzheimer＇s disease.To test this hypothesis,we used a previously established animal model of Alzheimer＇s disease,that is,microinjection of aggregated Aβ25–35 into the bilateral brain ventricles of Sprague-Dawley rats.We found that long-term（28 days） oral administration of Bushen Tiansui decoction（0.563,1.688,and 3.375 g/m L;4 m L/day） prevented synaptic loss in the hippocampus and increased the expression levels of synaptic proteins,including postsynaptic density protein 95,the N-methyl-D-aspartate receptor 2 B subunit,and Shank1.These results suggested that Bushen Tiansui decoction can protect synapses by maintaining the expression of these synaptic proteins.Bushen Tiansui decoction also ameliorated measures reflecting spatial learning and memory deficits that were observed in the Morris water maze（i.e.,increased the number of platform crossings and the amount of time spent in the target quadrant and decreased escape latency） following intraventricular injections of aggregated Aβ25–35 compared with those measures in untreated Aβ_（25–35）-injected rats.Overall,these results provided evidence that further studies on the prevention and treatment of dementia with this traditional Chinese medicine are warranted.
文摘[目的]观察复元填髓方治疗小脑共济失调综合征患者的疗效。[方法]纳入2024年2月至10月温州市中西医结合医院门诊就诊的小脑共济失调综合征患者29例,予以复元填髓方汤剂治疗12周,对比治疗前后患者国际合作共济失调量表(International Cooperative Ataxia Scale,ICARS)、共济失调等级量表(Scale for the Assessment and Rating of Ataxia,SARA)、日常生活活动能力(Activities of Daily Living,ADL)评分及中医证候量表的变化。[结果]共29例患者入组,其中27例完成12周疗程(脱落2例),治疗后患者ICARS评分缓解率为55.6%,维持率为25.9%;治疗前ICARS评分为(35.85±12.90)分,治疗后为(34.33±13.10)分,差异有统计学意义(P<0.05);SARA评分及中医症候量表评分均显著降低(P<0.05)。治疗期间,患者不良反应率为11.1%,其中腹泻3例。[结论]复元填髓方能够改善小脑共济失调综合征患者的共济失调症状以及肾虚髓亏证候。
